Granules India Buyback Offers Hope Amid Coronavirus Turmoil
Q4 Will Be Impacted By Coronavirus-Related Export Restrictions
Granules India’s buyback offer seems to be timed right. As the novel coronavirus crisis batters the Indian stock market, a 32% premium offered by the company is an attractive proposition for investors. However, its Q4 performance will see a blip on account of paracetamol export restrictions.
You may also be interested in...
A recent focus on high-margin generic formulations, strong contract manufacturing business, and expected cash inflow from stake sales in joint ventures could make Granules India an attractive buy for PE funds.
Aurobindo’s acquisition of 15 brands from Pfizer and Viatris to gain entry to Indonesia marks a role reversal of sorts as Pfizer has been licensing generics from Aurobindo. Scrip takes a look at some of the opportunities and challenges in this growing Southeast Asian market.
CEO of Enzene Biosciences weighs in on the impact of Medicare negotiations in the US on the biosimilars market even as a US filing is planned for a Prolia biosimilar. In the interview, he says Enzene “is not afraid or concerned” over ongoing litigation with Merck KGaA over an Erbitux biosimilar in India, adding that new modalities like ADCs are being “seriously” considered.